Diligence memo · auto-generated · as of July 2, 2026
Centaur Bio Inc.
Centaur Bio Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Centaur Bio Inc. operates in Pharmaceuticals, based in CHARLOTTE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Centaur Bio Inc. has raised $1.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $1.0M on 2024-03-05.
Most recent recorded round closed around 2024-03-05.
Valuation (modeled)modeled
Provath models Centaur Bio Inc. at approximately $5.5M (range $560K–$20M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.15× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 4 months.
Last raise 2.3 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 2.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 24% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 10% of those peers.
Closest niche peers: Eleison Pharmaceuticals Inc, Telomir Pharmaceuticals, Inc., Drusolv Therapeutics, Inc., TF Tech Ventures, Inc., Thyron Pharmaceuticals, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.